查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844100

脑肿瘤诊断市场按技术、产品、适应症、通路和最终用户划分－2025-2032年全球预测

Brain Cancer Diagnostics Market by Technology, Product, Indication, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，脑肿瘤诊断市场规模将达到 118.4 亿美元，复合年增长率为 12.80%。

主要市场统计数据
基准年 2024 45.2亿美元
预计年份：2025年 51.1亿美元
预测年份：2032年 118.4亿美元
复合年增长率 (%) 12.80%

对影响脑肿瘤诊断当前及近期未来的临床需求、诊断路径和监管驱动因素进行全面分析

本执行摘要重点在于当代脑肿瘤诊断生态系统，着重阐述影响诊断实践的临床需求、技术发展轨迹和相关人员的奖励。摘要首先概述了从症状出现到组织病理学确诊的诊断流程，重点强调了诊断准确性、週转时间和可及性如何影响患者预后。摘要还概述了先进影像技术、分子检测和传统病理工作流程之间的相互作用，以及这些诊断方式如何整合到多学科诊疗流程中。

引言也指出，监管的清晰度和基于价值的报销模式往往决定着一项创新能否从研究阶段走向常规临床应用，因此，监管考虑和研究动态是推动或阻碍技术采纳的重要因素。最后，引言为本概述的其余部分设定了预期：对变革性转变的评估、关税的影响、竞争考察、区域动态、竞争定位，以及为临床医生、诊断服务提供者和投资者提供策略指南的实用建议。

影像学、分子诊断和数位病理学领域的创新如何重新定义脑瘤诊断流程、数据整合和临床决策

脑肿瘤诊断正经历变革时期，主要得益于影像学、分子分析和数位病理学的融合。磁振造影通讯协定和混合成像技术的进步，使得病灶特征的表征更加精细，并能更可靠地区分肿瘤分级和治疗相关变化。同时，次世代定序和标靶PCR技术拓展了可用于诊断和治疗选择的分子特征，从而增强了精准诊断在治疗方案製定中的作用。

这些技术发展伴随着临床工作流程的演变，后者优先考虑微创取样和长期监测。液态切片方法和更精准的影像导引切片检查标靶技术降低了手术风险，同时提高了病人历程可获取的分子数据的频率和丰富度。此外，人工智慧和机器学习正被应用于扩展影像解读和组织病理学审查，从而实现更快的诊断并降低观察者间的差异。这些转变并非渐进式的；它们正在重塑多学科诊疗团队、数据管治模式以及供应商与医疗机构之间的伙伴关係，促使医疗机构重新评估其诊断平台以及耗材和资讯技术方面的资金投入。

评估2025年关税和贸易调整如何重塑脑肿瘤诊断供应链的筹资策略、供应商多元化和成本控制。

2025年关税调整和贸易政策调整的累积影响，对供应链和成本带来了多重压力，供应商和製造商必须积极应对。进口设备零件、试剂和影像处理硬体关税的提高，正在改变诊断实​​验室和医院的采购策略，迫使各机构探索替代筹资策略、重新谈判供应商合同，并建立本地化的库存缓衝，以维持临床服务的连续性。

这些不利因素也加速了关于供应商多元化以及关键试剂和影像耗材近岸外包的讨论。诊断服务提供者正在权衡短期价格上涨与长期供应稳定性的益处，通常选择投资于维护和培训服务，以延长设备的使用寿命。同时，一些製造商正在透过调整产品系列和包装来应对，以减轻关税的影响，或加强与监管机构和支付方利益相关人员的沟通，以证明其临床价值提案，从而获得更高的报销，抵消增加的营运成本。因此，筹资策略、合约灵活性和营运应急计画在市场上的重要性正变得与临床差异化同等重要。

多维度的细分观点揭示了技术类型、产品类型、临床适应症、分销管道和最终用户如何影响技术采纳和临床影响。

深入的市场细分阐明了技术、产品组合、临床适应症、分销管道和终端用户画像如何共同决定产品需求和市场接受度。 CT、MRI 和 PET 等影像学技术可提供结构和功能方面的信息，指南手术方案製定并监测治疗反应。分子诊断技术，包括次世代定序和 PCR 方法，可提供基因组和转录组信息，并为标靶治疗和临床试验註册提供依据。

从产品类型角度来看，耗材和试剂（包括套件和探针）是分子检测通量的主要来源，而诊断系统、成像系统和检测设备则构成决定检测能力和通量的基础设施。设备维护、培训和技术支援等服务对于维持诊断品质和运作至关重要。就临床适应症而言，不同肿瘤类型的诊断需求各不相同，包括星状细胞瘤、多形性胶质母细胞瘤、脑膜瘤和寡树突胶质瘤。多形性胶质母细胞瘤病例通常需要快速的多模态诊断以製定积极的治疗方案，而脑膜瘤的评估通常依赖影像学特征和手术病理。分销管道动态表明，线下关係对于复杂的安装和临床医生参与仍然至关重要，而线上管道在耗材采购和资讯传播方面的影响力日益增强。诊断实验室优先考虑通量、验证和合规性；医院优先考虑整合工作流程和多学科协作；而研发部门则优先考虑分析灵活性和检测方法开发能力。了解这些细分市场如何相互作用，有助于明确创新投资和商业性努力可以在哪些方面带来最强劲的临床和经济回报。

美洲、欧洲、中东和非洲以及亚太地区的区域动态和基础设施存在差异，这些差异会影响诊断应用管道和策略重点。

区域动态是我们策略的核心，因为美洲、欧洲、中东和非洲以及亚太地区的临床实践模式、法规环境和医疗基础设施存在显着差异。美洲的医疗体系往往以高度先进的三级医疗中心为特征，这些中心拥有完善的报销机制和庞大的研究网络，并且越来越多地采用尖端影像和分子诊断技术。这使得创新成果能够迅速转化为临床应用，但也对具有明确临床效用的差异化诊断技术提出了更高的竞争要求。

在欧洲、中东和非洲，分散的法律规范和差异化的报销环境往往促使供应商采取针对特定国家的策略，与当地经销商和学术中心合作，以检验临床和经济价值。同时，亚太地区既有快速发展的都市区医疗体系，也有资源匮乏的环境。主要市场的大型教学医院和研究机构推动了新一代定序（NGS）和先进影像技术的应用，而中东和非洲其他地区则优先考虑经济高效、可扩展的诊断方法和稳健的供应链解决方案。在这些全部区域，当地临床实践、基础设施准备和商业模式的相互作用，将决定製造商应优先投资于哪些方面的培训、服务网络和循证实践，以支持技术的推广应用。

竞争动态揭示了现有企业、分子专家和敏捷创新者如何透过伙伴关係、证据和服务产品来定位自身。

脑肿瘤诊断领域的竞争格局呈现出多元化的特点，既有成熟的影像和实验室设备製造商，也有专注于分子诊断的专业公司，以及致力于人工智慧辅助解读和新型检测技术的新兴企业。现有影像设备供应商透过配套服务协议和长期维护合约与医院和神经外科中心保持紧密的合作关係，这导致转换成本高昂，但也为在混合影像和工作流程整合方面开展合作创造了机会。分子诊断公司则透过检测范围广、检测灵敏度高以及针对临床终点的验证来脱颖而出，并经常与学术中心合作进行前瞻性评估和指南整合。

规模较小的创新者凭藉单项分析物检测或增强放射学和病理学解读的人工智慧演算法，开闢了利基市场，并经常寻求与大型製造商达成合作开发或许可协议以扩大销售。那些产品与临床医生工作流程相契合、提供可靠的真实世界证据并透过培训和服务支持实施的公司，更有可能确保产品的持续应用。策略联盟、技术授权和有针对性的收购仍然是市场参与企业扩展自身能力和地理覆盖范围的主要途径。

为产业领导者提供可操作的策略重点，以协调产品创新、供应链韧性、证据产生和临床应用这四项重要任务。

这意味着要投资于整合影像、分子数据和病理学的综合诊断解决方案；透过策略采购和服务模式增强供应链韧性；并建立健全的证据生成机制，以证明其临床效用和经济价值。优先采用综合解决方案可以减少临床工作流程中的摩擦，并促进与医疗服务提供者建立更深的联繫。对维护、培训和远端支援的投资也有助于降低停机风险，并提高客户维繫。

同时，企业应采用灵活的商业模式，既适应集中式实验室工作流程，也适应就地检验模式，并逐步渗透到医院系统和专科诊断实验室。证据的产生需要前瞻性临床检验和卫生经济学分析，这些分析必须能够引起支付方和医院采购委员会的共鸣。最后，与学术中心和患者权益组织建立伙伴关係，将加快获得检验临床队列，从而提高指南采纳和临床医生认可的可能性。

一项严谨的混合方法研究途径将结合一手研究（包括临床医生访谈）和二手文献，以检验诊断性能和实施方面的见解。

该分析整合了对临床专家、实验室主任和行业高管的访谈以及二手研究，包括同行评审文献、监管出版物和技术白皮书。定性访谈深入分析了临床工作流程、诊断路径中的痛点以及医院和诊断实验室面临的实际限制。二级资讯来源用于验证技术能力、监管里程碑和公共部门采购趋势，特别关注近期同行评审的、检验诊断性能指标和实施结果的研究。

我们采用多层检验流程加强资料完整性，包括将技术属性与製造商的技术规格进行交叉检验，并咨询独立的临床病理学家。我们记录了经验证据仍然匮乏的领域，例如跨地区和跨机构类型的抽样，以及某些新兴液态切片方法的临床效用，从而解决了局限性和潜在偏差。在可行的情况下，我们优先考虑可重复的临床观察和经验丰富的从业者的共识观点，以确保我们的分析具有实用性和与临床实际情况的相关性。

本概要简要介绍了将诊断技术进步转化为改善患者预后所需的技术、证据和营运策略的整合。

总之，脑肿瘤诊断领域正朝着整合的、数据丰富的诊断生态系统转型，该系统融合了先进的影像技术、分子谱分析和优化的病理工作流程。这一发展方向为提高诊断准确性和实现个体化治疗方案提供了巨大机会，但要充分发挥其潜力，需要在技术整合、临床医生培训和循证医学证据生成方面进行协调一致的投资。同时，不断变化的贸易动态以及监管和报销环境的区域差异，也要求制定适应性强的商业策略和建构具有韧性的供应链。

因此，决策者应着重于实现不同模式间的互通性，以令人信服的真实世界证据支持临床应用，并设计灵活的交付模式以满足不同医疗机构的需求。将技术创新与切实可行的应用管道和相关人员的参与相结合，可以加速诊断技术的进步转化为患者疗效的改善，同时保持营运和财务的永续性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 利用新一代定序技术进行个人化脑肿瘤分子谱分析
  • 将人工智慧演算法整合到 MRI 分析中以提高诊断准确性
  • 开发液态生物检体检测方法，用于非侵入性检测神经胶母细胞瘤的復发和进展。
  • 用于同时检测神经蛋白生物标记的多重免疫检测盒的出现
  • 拓展远端医疗平台，促进远距神经影像和跨学科协作
  • PET追踪剂在标靶肿瘤代谢、用于脑肿瘤早期检测和监测的进展
  • 监管部门的核准推动了照护现场胶质瘤诊断设备在临床环境中的商业化。
  • 整合精准医学影像、基因体学和蛋白质体学资料的综合诊断平台发展迅速
  • 製药公司和诊断公司合作开发脑瘤伴随检测
  • 新兴市场对经济高效的筛检解决方案的需求日益增长，以提高脑肿瘤的早期检测率

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章 脑肿瘤诊断市场（依技术划分）

  • 基因检测
  • 影像
    • 电脑断层扫描
    • MRI
    • PET
  • 分子诊断
    • NGS
    • PCR
  • 病理
    • 切片检查分析
    • 组织病理学

第九章 脑肿瘤诊断产品市场

  • 耗材和试剂
    • 套件
    • 探针和试剂
  • 装置
    • 诊断系统
    • 影像系统
    • 实验室设备
  • 服务
    • 维护
    • 培训和支持

第十章 脑肿瘤诊断市场（依适应症划分）

  • 星状细胞瘤
  • 多形性胶质母细胞瘤
  • 脑膜瘤
  • 寡树突胶质瘤

第十一章 脑肿瘤诊断市场（依通路划分）

  • 离线
  • 在线的

第十二章 脑肿瘤诊断市场（依最终用户划分）

  • 诊断实验室
  • 医院
  • 研究所

第十三章 脑肿瘤诊断市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 脑肿瘤诊断市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国脑瘤诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • General Electric Company
    • Siemens Healthineers AG
    • Koninklijke Philips NV
    • Canon Medical Systems Corporation
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Illumina, Inc.
    • Abbott Laboratories
    • Agilent Technologies, Inc.
Product Code: MRR-A26E0E57412A

The Brain Cancer Diagnostics Market is projected to grow by USD 11.84 billion at a CAGR of 12.80% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.52 billion
Estimated Year [2025] USD 5.11 billion
Forecast Year [2032] USD 11.84 billion
CAGR (%) 12.80%

Comprehensive situational framing of clinical imperatives, diagnostic pathways, and regulatory drivers shaping the present and near-term future of brain cancer diagnostics

This executive summary introduces a focused analysis of the contemporary brain cancer diagnostics ecosystem, emphasizing clinical needs, technological trajectories, and stakeholder incentives that are shaping diagnostic practice. The narrative begins by framing the diagnostic journey from symptom presentation through to histopathological confirmation, highlighting where diagnostic accuracy, turnaround time, and accessibility intersect to influence patient outcomes. It outlines the interplay between advanced imaging modalities, molecular assays, and traditional pathology workflows, and how these modalities are being integrated into multi-disciplinary care pathways.

The introduction also situates regulatory considerations and reimbursement dynamics as critical enablers or impediments to adoption, noting that regulatory clarity and value-based reimbursement models frequently determine whether innovations transition from research settings into routine clinical use. Finally, the introduction sets expectations for the remainder of the summary: an assessment of transformative shifts, tariff impacts, segmentation insights, regional dynamics, competitive positioning, and practical recommendations to guide strategy for clinicians, diagnostics providers, and investors.

How converging imaging, molecular diagnostics, and digital pathology innovations are redefining diagnostic workflows, data integration, and clinical decision-making for brain tumors

The diagnostic landscape for brain tumors is undergoing a transformative shift driven by convergence across imaging, molecular analysis, and digital pathology. Advances in magnetic resonance imaging protocols and hybrid imaging techniques are refining lesion characterization, enabling more confident distinctions between tumor grades and treatment-related changes. Concurrently, next-generation sequencing and targeted PCR panels are expanding the molecular fingerprints available for diagnosis and therapeutic selection, thereby elevating the role of precision diagnostics in care planning.

These technological developments are accompanied by evolving clinical workflows that prioritize minimally invasive sampling and longitudinal monitoring. Liquid biopsy approaches and improved biopsy targeting through image guidance are reducing procedural risk while increasing the frequency and richness of molecular data available across the patient journey. Moreover, artificial intelligence and machine learning are being deployed to augment image interpretation and histopathology review, accelerating diagnostic turnaround and reducing inter-observer variability. Collectively, these shifts are not merely incremental; they are reconfiguring multidisciplinary care teams, data governance models, and vendor-provider partnerships, and are prompting institutions to reassess capital allocation for diagnostic platforms versus consumables and informatics.

Assessing how 2025 tariff and trade adjustments are reshaping procurement strategies, supplier diversification, and cost management across brain cancer diagnostic supply chains

The cumulative impact of tariff changes and trade policy adjustments in 2025 has introduced a layer of supply chain and cost pressure that providers and manufacturers must actively manage. Increased duties on imported instrumentation components, reagents, and imaging hardware have altered procurement calculus for diagnostic laboratories and hospitals, leading organizations to explore alternative sourcing strategies, renegotiated supplier contracts, and localized inventory buffers to preserve clinical continuity.

These trade headwinds have also accelerated discussions around supplier diversification and nearshoring for critical reagents and imaging consumables. Diagnostic providers are balancing the short-term implications of higher landed costs against the long-term benefits of supply resilience, often choosing to invest in maintenance and training services to extend equipment lifecycle performance. At the same time, some manufacturers have reacted by adjusting product portfolios and packaging to mitigate tariff exposure, or by increasing engagement with regulatory authorities and payer stakeholders to demonstrate clinical value propositions that justify higher reimbursement to offset increased operational expense. The net result is a marketplace where procurement strategies, contracting agility, and operational contingency planning have become as important as clinical differentiation.

A multidimensional segmentation perspective revealing how technology types, product categories, clinical indications, distribution channels, and end users shape adoption and clinical impact

Insightful segmentation underscores how technology, product composition, clinical indication, distribution channels, and end-user profiles jointly determine product demand and adoption pathways. When the market is considered by technology, genetic testing, imaging, molecular diagnostics, and pathology each contribute distinct value propositions: imaging modalities such as CT, MRI, and PET provide structural and functional insights that guide surgical planning and monitor response; molecular diagnostics, split into next-generation sequencing and PCR approaches, deliver genomic and transcriptomic context that informs targeted therapies and clinical trial enrollment; pathology workflows encompassing biopsy analysis and histopathology remain the diagnostic anchor, integrating morphological assessment with ancillary molecular data.

Viewed through the lens of product types, consumables and reagents including kits and probes enable much of the molecular testing throughput, while diagnostic systems, imaging systems, and lab instruments form the capital infrastructure that dictates testing capacity and throughput. Services such as equipment maintenance, training, and technical support are critical to sustaining diagnostic quality and uptime. Considering clinical indications, diagnostic needs differ across tumor classes including astrocytoma, glioblastoma multiforme, meningioma, and oligodendroglioma; glioblastoma multiforme cases often demand rapid, multimodal diagnostics for aggressive treatment planning, whereas meningioma evaluation may rely more heavily on imaging characteristics and surgical pathology. Distribution channel dynamics reveal that offline relationships remain essential for complex installations and clinician engagement, while online channels are increasingly influential for consumables procurement and information dissemination. Finally, end-user segmentation shows divergent priorities: diagnostic laboratories emphasize throughput, validation, and compliance; hospitals prioritize integrated workflows and multidisciplinary coordination; research institutes prioritize analytical flexibility and assay development capacity. Understanding how these segments interact clarifies where innovation investments and commercial efforts will yield the strongest clinical and economic returns.

Regional dynamics and infrastructure contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption pathways and strategic priorities for diagnostics

Regional dynamics are central to strategy because clinical practice patterns, regulatory environments, and healthcare infrastructure vary substantially across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems tend to feature advanced tertiary centers with high adoption of cutting-edge imaging and molecular diagnostics, supported by established reimbursement mechanisms and sizable research networks. This enables rapid translation of innovations into clinical pathways but also creates competitive pressure for differentiated diagnostics that demonstrate clear clinical utility.

In Europe, Middle East & Africa, fragmented regulatory frameworks and heterogeneous reimbursement environments prompt vendors to pursue country-level strategies, often partnering with regional distributors and academic centers to validate clinical and economic value. Meanwhile, Asia-Pacific presents a mix of high-growth urban health systems and resource-constrained settings; large academic hospitals and research institutes in major markets drive adoption of NGS and advanced imaging, while other areas prioritize cost-effective, scalable diagnostics and robust supply chain solutions. Across these regions, the interplay between local clinical practice, infrastructure readiness, and commercial models dictates where manufacturers should prioritize investments in training, service networks, and evidence generation to support uptake.

Competitive landscape dynamics revealing how incumbents, specialized molecular firms, and agile innovators are positioning through partnerships, evidence, and service offerings

Competitive landscapes in brain cancer diagnostics are characterized by a mix of established imaging and laboratory instrument manufacturers, specialized molecular diagnostics firms, and emerging players focused on AI-driven interpretation or novel assay chemistries. Incumbent imaging vendors maintain strong relationships with hospitals and neurosurgical centers through bundled service agreements and long-term maintenance contracts, which creates high switching costs but also opens opportunities for partnerships on hybrid imaging and workflow integration. Molecular diagnostics companies differentiate through panel breadth, assay sensitivity, and validation against clinical endpoints, often collaborating with academic centers for prospective evaluation and guideline inclusion.

Smaller innovators are carving niche positions with single-analyte tests or AI algorithms that augment radiological and pathological interpretation, and they often seek co-development or licensing agreements with larger manufacturers to scale distribution. Across the competitive spectrum, companies that align their offerings with clinician workflows, provide robust real-world evidence, and support implementation through training and service are most likely to secure sustained adoption. Strategic alliances, technology licensing, and targeted acquisitions remain the primary routes by which market participants expand capabilities and geographic reach.

Actionable strategic priorities for industry leaders to align product innovation, supply chain resilience, and evidence generation with clinical adoption imperatives

Industry leaders should pursue a three-pronged approach to maximize clinical impact while preserving commercial resilience: invest in integrated diagnostic solutions that combine imaging, molecular data, and pathologic context; strengthen supply chain resilience through strategic sourcing and service models; and build robust evidence generation programs that demonstrate clinical utility and economic value. Prioritizing integrated solutions reduces friction in clinical workflows and fosters deeper institutional relationships, while investment in maintenance, training, and remote support mitigates downtime risk and enhances customer retention.

In parallel, companies should adopt flexible commercial models that accommodate both centralized laboratory workflows and point-of-care testing paradigms, enabling penetration across hospital systems and specialized diagnostic laboratories. Evidence generation must include prospective clinical validation and health-economic analyses that resonate with payers and hospital procurement committees. Finally, cultivating partnerships with academic centers and patient advocacy groups accelerates access to clinical cohorts for validation and increases the likelihood of guideline adoption and clinician endorsement.

Rigorous mixed-method research approach combining primary clinician engagement and secondary literature synthesis to validate diagnostic performance and implementation insights

This analysis synthesizes primary interviews with clinical experts, laboratory directors, and industry executives, together with secondary research across peer-reviewed literature, regulatory publications, and technology white papers. Primary qualitative engagements informed perspectives on clinical workflows, pain points in diagnostic pathways, and practical constraints faced by hospitals and diagnostic laboratories. Secondary sources were used to triangulate technology capabilities, regulatory milestones, and public sector procurement trends, with particular attention to recent peer-reviewed studies that validate diagnostic performance metrics and implementation outcomes.

Data integrity was reinforced through a multi-layered validation process that included cross-verification of technological attributes with manufacturer technical specifications and consultation with independent clinical pathologists. Limitations and potential biases were addressed by sampling across geographies and facility types, and by documenting areas where empirical evidence remains nascent, such as clinical utility for certain emerging liquid biopsy approaches. Wherever possible, conclusions prioritize reproducible clinical findings and consensus viewpoints from experienced practitioners to ensure the analysis is actionable and grounded in clinical reality.

Concise synthesis emphasizing the integration of technology, evidence, and operational strategy needed to translate diagnostic advances into improved patient outcomes

In conclusion, the brain cancer diagnostics arena is transitioning toward integrated, data-rich diagnostic ecosystems that combine advanced imaging, molecular profiling, and enhanced pathology workflows. This trajectory offers meaningful opportunities to improve diagnostic precision and to personalize treatment selection, but realizing that potential requires coordinated investments in technology integration, clinician training, and evidence generation. At the same time, evolving trade dynamics and regional variations in regulatory and reimbursement environments necessitate adaptive commercial strategies and resilient supply chains.

Decision-makers should therefore focus on enabling interoperability across modalities, supporting clinical adoption with compelling real-world evidence, and designing flexible delivery models that accommodate diverse institutional needs. By aligning technological innovation with pragmatic implementation pathways and payer engagement, stakeholders can accelerate the translation of diagnostic advances into improved patient outcomes while maintaining operational and financial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of next generation sequencing for personalized brain tumor molecular profiling
  • 5.2. Integration of artificial intelligence algorithms in MRI analysis to improve diagnostic accuracy
  • 5.3. Development of liquid biopsy assays for noninvasive detection of glioblastoma recurrence and progression
  • 5.4. Emergence of multiplex immunoassay panels for simultaneous detection of neural protein biomarkers
  • 5.5. Expansion of telemedicine platforms for remote neuroimaging review and multidisciplinary consultation
  • 5.6. Advancements in PET tracers targeting tumor metabolism for earlier brain cancer detection and monitoring
  • 5.7. Regulatory approvals driving commercialization of point-of-care glioma diagnostic devices in clinical settings
  • 5.8. Growth of integrated diagnostic platforms combining imaging, genomics, and proteomics data for precision medicine
  • 5.9. Increasing collaboration between pharmaceutical and diagnostic firms to co-develop companion brain cancer tests
  • 5.10. Rising demand for cost-effective screening solutions in emerging markets to improve brain tumor early detection rates

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Cancer Diagnostics Market, by Technology

  • 8.1. Genetic Testing
  • 8.2. Imaging
    • 8.2.1. CT Scan
    • 8.2.2. MRI
    • 8.2.3. PET
  • 8.3. Molecular Diagnostics
    • 8.3.1. NGS
    • 8.3.2. PCR
  • 8.4. Pathology
    • 8.4.1. Biopsy Analysis
    • 8.4.2. Histopathology

9. Brain Cancer Diagnostics Market, by Product

  • 9.1. Consumables & Reagents
    • 9.1.1. Kits
    • 9.1.2. Probes & Reagents
  • 9.2. Equipment
    • 9.2.1. Diagnostic Systems
    • 9.2.2. Imaging Systems
    • 9.2.3. Lab Instruments
  • 9.3. Services
    • 9.3.1. Maintenance
    • 9.3.2. Training & Support

10. Brain Cancer Diagnostics Market, by Indication

  • 10.1. Astrocytoma
  • 10.2. Glioblastoma Multiforme
  • 10.3. Meningioma
  • 10.4. Oligodendroglioma

11. Brain Cancer Diagnostics Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Brain Cancer Diagnostics Market, by End User

  • 12.1. Diagnostic Laboratories
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Brain Cancer Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. General Electric Company
    • 16.3.2. Siemens Healthineers AG
    • 16.3.3. Koninklijke Philips N.V.
    • 16.3.4. Canon Medical Systems Corporation
    • 16.3.5. F. Hoffmann-La Roche Ltd.
    • 16.3.6. Thermo Fisher Scientific Inc.
    • 16.3.7. QIAGEN N.V.
    • 16.3.8. Illumina, Inc.
    • 16.3.9. Abbott Laboratories
    • 16.3.10. Agilent Technologies, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRAIN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS,